Physician profile
Sharon S Meyer
NPI 1518934611
$5,126.13
in general payments reported to CMS, 2019-2025
29 companies · $1,892 in 2025
The $1,892 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $512 · 2020: $227 · 2021: $185 · 2022: $957 · 2023: $768 · 2024: $585 · 2025: $1,892.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,150 · Education: $94.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,149.67 |
| Education | $94.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $866.62 | 2019-2025 | |
| Genzyme Corporation | $461.69 | 2021-2025 | |
| Janssen Biotech, INC. | $460.91 | 2020-2025 | Tremfya |
| Arcutis Biotherapeutics, INC. | $435.44 | 2023-2025 | Zoryve |
| Leo Pharma INC. | $270.91 | 2022-2025 | Anzupgo, Adbry |
| Incyte Corporation | $236.29 | 2022-2025 | Opzelura |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $235.23 | 2019-2021 | |
| Merz North America, INC. | $233.06 | 2019-2023 | Xeomin |
| Galderma Laboratories, L.P. | $227.24 | 2020-2025 | Dysport |
| Dermavant Sciences, INC. | $216.99 | 2022-2024 | Vtama |
| Novartis Pharmaceuticals Corporation | $213.06 | 2019-2025 | |
| Lilly USA, LLC | $188.67 | 2022-2025 | Ebglyss, Taltz |
| Organon LLC | $174.21 | 2025 | Vtama |
| Vyne Pharmaceuticals INC. | $156.89 | 2020-2021 | |
| Ucb, INC. | $148.76 | 2019-2022 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dermira, INC. | $125.00 | 2019 | |
| Revance Therapeutics, INC. | $87.86 | 2024 | Daxxify |
| E.R. Squibb & Sons, L.L.C. | $81.60 | 2023-2025 | Sotyktu |
| Regeneron Healthcare Solutions, INC. | $55.51 | 2025 | Dupixent |
| Amgen INC. | $46.88 | 2024-2025 | Otezla, Otezla |
| Pacira Pharmaceuticals Incorporated | $33.20 | 2023-2024 | Exparel, Zilretta, Iovera |
| Sun Pharmaceutical Industries INC. | $29.38 | 2023 | Winlevi, Absorica Ld |
| Ardelyx, INC. | $28.80 | 2024 | Ibsrela |
| Pfizer INC. | $26.97 | 2019-2025 | |
| Paratek Pharmaceuticals, INC. | $19.83 | 2024 | Nuzyra |
| Allergan, INC. | $19.50 | 2022 | |
| Botanix Sb INC | $17.40 | 2025 | Sofdra |
| Medtronic, INC. | $14.57 | 2021 | |
| Ethicon US, LLC | $13.66 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sharon Meyer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.